Aravis and Proquest back Telormedix

The capital will allow Telormedix to further develop its product candidates through preclinical and clinical trials.

Previously, Aravis Ventures led a CHF21m funding round for Telormedix joined by Proquest in October 2008.

Company
Bioggio-based Telormedix was founded in October 2007 and is a biotechnology company specialising in treatments for cancer and autoimmune diseases. The company's product TMX-101 is currently in a phase I/II clinical trial for the treatment of non-muscle invasive bladder cancer. Telormedix is also working on the products TMX-201 and TMX-202 which can be applied as vaccine adjuvants.

People
Jean-Philippe Tripet is managing partner and founder of Aravis and Alain Schreiber is general partner at ProQuest Investments.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland